2009年5月29日,博士伦公司宣布美国食品药品管理局(FDA)批准0.6% Besivance(贝西沙星混悬型滴眼液)用于治疗细菌性结膜炎(俗名“红眼病”)。Besivance是一种局部眼用制剂,加入无菌滴眼剂给药,为针对眼部致病菌(其中包括细菌性结膜炎的最常见致病菌)的广谱抗菌药。据生产商称,Besivance是第一个专用针对眼部研发的氟喹诺酮类药物,也是第一个且惟一一个既往未全身应用的眼用氟喹诺酮类药物。 FDA基于8项临床试验的结果批准Besivance的应用。这些研究旨在检测此局部抗菌药的疗效、安全性、耐药性、药代动力学以及药效动力学。有3项多中心、随机、双盲试验对Besivance的疗效进行了评价,共纳入了近2,400例临床上诊断为细菌性结膜炎的患者。在临床试验中,与接受仅含防腐剂的对照液处置的患者相比,接受Besivance治疗的患者感染消除速率较快。 研究表明,Besivance可有效治疗年龄≥1岁的患者。 Besivance适用于治疗年龄≥1岁、由下列细菌的致病分离物所致的细菌性结膜炎患者:CDC棒状杆菌G群,假白喉棒杆菌,纹带棒杆菌,流感嗜血杆菌,腔隙莫拉菌,金黄色葡萄球菌,表皮葡萄球菌,人葡萄球菌,路邓葡萄球菌,缓症链球菌群,口腔链球菌,肺炎链球菌以及唾液链球菌。值得一提的是,Besivance针对上述某些细菌的疗效测试是在不足10例的感染患者中进行的。 制造商: 药理分类: 活性成分(补): 药理作用: 该产品是治疗由过敏表示要对以下细菌引起的细菌性结膜炎的菌株:中华网棒形G组,棒状杆菌pseudodiphtheriticum,纹状体棒状杆菌,流感嗜血杆菌,莫拉lacunata,金黄色葡萄球菌,表皮葡萄球菌,金黄色葡萄球菌hominus,金黄色葡萄球菌lugdunensis,缓症链球菌群,口腔链球菌,肺炎链球菌,唾液链球菌。 与其他抗感染,对besifloxacin长时间使用可能导致非敏感微生物过度生长,计有真菌。如果超感染,就会停止使用,并制定替代疗法。跳绳剂量或不能完成整个疗程的治疗可能会降低,直接的治疗效果,增加的可能性,细菌会产生耐药性,不会被besifloxacin或将来在其他抗菌药物治疗。 Besivance是外用眼科只使用,不应该被注入结膜,也不应该被引入到眼睛前房直接。 临床试验: 法律分类: 成人和儿童: 警告/注意事项: 不良反应(补): 注释: 如何提供: 最后更新: Manufacturer:Bausch & Lomb Pharmaceuticals Pharmacological Class:Quinolone Active Ingredient(s):Besifloxacin 0.6%; oph. susp; contains benzalkonium chloride. Indication(s):Susceptible bacterial conjunctivitis. Pharmacology:Besifloxacin is a fluoroquinolone with activity against a variety of gram (+) and gram (-) bacteria. Like others in its class, it works by inhibiting bacterial DNA gyrase, which is necessary for replication, transcription, and repair of bacterial DNA, and topoisomerase IV, which is necessary for the partitioning of chromosomal DNA during cell division. It has a different mode of action than that of the aminoglycosides, macrolides, and β-lactam antibiotics, and may therefore provide coverage against pathogens that are resistant to these other antibiotics. Clinical Trials:A randomized, double-masked, vehicle-controlled clinical trial was conducted in which patients with bacterial conjunctivitis were dosed with besifloxacin 0.6% ophthalmic suspension three times daily for 5 days. In this trial, besifloxacin was shown to be superior to vehicle in clinical resolution (45% vs. 33%, respectively). Microbiological outcomes showed a statistically significant eradication rate for causative pathogens for besifloxacin compared to vehicle (91% vs. 60%, respectively). Legal Classification:Rx Adults & Children:<1yr: not recommended. ≥1year: 1 drop in affected eye(s) 3 times daily (4–12 hrs apart) for 7 days. Shake bottle once before use. Warnings/Precautions:Remove contact lenses during therapy or if symptomatic. Pregnancy (Cat.C). Nursing mothers. Adverse Reaction(s):Conjunctival redness, blurred vision, eye pain/pruritus/irritation, headache; superinfection (discontinue and treat). Notes:Avoid contaminating the applicator tip with material from the eye, fingers, or other source. Wash hands thoroughly prior to use. Invert closed bottle and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back, and with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s). How Supplied:Susp—5mL |